{
    "id": 20354,
    "fullName": "NFE2L2 dec exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "NFE2L2 dec exp indicates decreased expression of the Nfe2l2 protein. However, the mechanism causing the decreased expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4780,
        "geneSymbol": "NFE2L2",
        "terms": [
            "NFE2L2",
            "HEBP1",
            "IMDDHH",
            "Nrf-2",
            "NRF2"
        ]
    },
    "variant": "dec exp",
    "createDate": "03/28/2016",
    "updateDate": "08/23/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19444,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Trisenox (arsenic trioxide) treatment reduced viability, and induced endoplasmic reticulum-stress and apoptosis in a pancreatic ductal adenocarcinoma cell line with decreased NFE2L2 expression in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 31420604).",
            "molecularProfile": {
                "id": 20808,
                "profileName": "NFE2L2 dec exp"
            },
            "therapy": {
                "id": 640,
                "therapyName": "Arsenic trioxide",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17081,
                    "pubMedId": 31420604,
                    "title": "Synergy between arsenic trioxide and JQ1 on autophagy in pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31420604"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5001,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knockdown of NFE2L2 increased sensitivity of Femara (letrozole)-resistant breast cancer cell lines to Aromasin (exemestane) in culture (PMID: 25976679).",
            "molecularProfile": {
                "id": 20808,
                "profileName": "NFE2L2 dec exp"
            },
            "therapy": {
                "id": 738,
                "therapyName": "Exemestane",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4830,
                    "pubMedId": 25976679,
                    "title": "Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25976679"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 20808,
            "profileName": "NFE2L2 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}